Broken String Biosciences, a biotechnology company enabling gene editing teams to accelerate development of safer, more effective genetic medicines, has launched BaseMap ABE. Built on the company’s INDUCE-seq technology, BaseMap ABE extends the platform’s capabilities to support adenine base editing (ABE) applications.

Base editing is rapidly gaining momentum as a powerful therapeutic tool that enables precise single-base genomic changes. However, as therapeutic programmes increasingly adopt ABE, researchers require reproducible and standardised methods to comprehensively characterise unintended off-target editing events.

Unlike prediction-based approaches, BaseMap ABE generates genome-wide data directly from biologically relevant cells, providing researchers with clear understanding of editor specificity under physiologically relevant conditions. The company says the platform enables rapid, unbiased identification of off-target events, while generating standardised and robust data to support guide optimisation, editor selection and preclinical decision making.

BaseMap ABE represents the first phase of Broken String Biosciences’ expansion into base editing applications, building on its INDUCE-seq technology. Through the Early Access Program, the company will collaborate with researchers developing genome editing therapies, providing first-hand experience for early adopters and generating feedback to inform future product development.

Terry Pizzie, CEO of Broken String Biosciences, said: “As gene editing technologies evolve, researchers need to wholly understand where and how frequently off-target editing occurs. By extending our product portfolio to support ABE, Broken String is enabling scientists to characterise editing outcomes for one of the most promising next-generation editing modalities. We are excited to get this solution into the hands of early-adopters – working closely with them to shape the future of our product and support the development of safe and effective base editing therapeutics.”